In a 76-year-old male nursing-home resident taking levetiracetam 500 mg twice daily with a serum level of 5.7 µg/mL, should the dose be adjusted?

Management of Subtherapeutic Levetiracetam Level in a 76-Year-Old Nursing Home Resident

In this 76-year-old nursing home resident with a levetiracetam level of 5.7 µg/mL (below the therapeutic range of 12-46 µg/mL), you should strongly consider deprescribing the medication entirely if he is bed-bound with limited life expectancy and has had no documented seizures in the past 6-12 months. 1

Initial Clinical Decision Framework

The first critical step is determining whether this resident has experienced any recent breakthrough seizures, as this dictates whether to deprescribe versus optimize therapy. 1

• Review nursing documentation for the preceding 30 days and interview staff to identify any witnessed seizure activity, as breakthrough seizures signify true therapeutic failure requiring intervention. 1
• Verify medication administration records to assess compliance, since non-adherence is the most common cause of subtherapeutic levetiracetam levels in nursing home populations. 1
• Assess functional status, particularly whether the resident is bed-bound, as this reflects advanced frailty and is a key factor in deprescribing decisions. 1

Deprescribing Pathway (Preferred for Frail, Bed-Bound Residents)

Deprescribing levetiracetam should be strongly considered in bed-bound residents with limited life expectancy unless recent seizure activity is documented. 1

• Bed-bound status reflects advanced frailty, making continued antiepileptic prophylaxis without recent seizures low-value care in this population. 1
• If no seizures have occurred in the past 6-12 months, taper levetiracetam by 250-500 mg every 1-2 weeks while monitoring for breakthrough events, as the drug may no longer be necessary and contributes to polypharmacy. 1
• Residents in nursing homes fall under STOPP-NH and NORGEP-NH criteria, which advise systematic evaluation of all preventive medications for appropriateness. 1

Dose Optimization Pathway (If Recent Seizures Documented)

When documented seizures have occurred within the past 6 months or the resident has high-risk seizure etiology (prior stroke, brain tumor, traumatic brain injury), therapy should be optimized rather than deprescribed. 1

Dosing Adjustments

• Increase levetiracetam to 1000 mg twice daily (from the current 500 mg twice daily) as the minimum dose shown to achieve therapeutic concentrations in elderly patients with normal renal function. 1
• The current level of 5.7 µg/mL is subtherapeutic (therapeutic range 12-46 µg/mL), and the standard 500 mg twice daily dose is insufficient. 2, 3

Renal Function Considerations

Assess creatinine clearance before dose escalation, as levetiracetam is 66% renally excreted unchanged and clearance is directly dependent on renal function. 4, 2

Renal-adjusted dosing recommendations: 1

Creatinine Clearance	Recommended Dose (every 12 hours)
≥50 mL/min	500-1500 mg
30-50 mL/min	500-750 mg
<30 mL/min	250-500 mg

• In elderly patients, care should be taken in dose selection as they are more likely to have decreased renal function, and it may be useful to monitor renal function. 4
• The elimination half-life in elderly volunteers is 10-11 hours (compared to 6-8 hours in younger adults), requiring consideration for dose adjustments. 2

Critical Safety Considerations

• Do not add a second antiepileptic drug before maximizing the tolerated dose of levetiracetam monotherapy, as additional agents increase fall risk and drug-interaction potential in frail elderly patients. 1
• Monitor for adverse effects including somnolence, asthenia, CNS depression, and behavioral changes, which are common and can be very problematic in older patients. 5
• In bed-bound residents without recent seizures, prioritize deprescribing to enhance quality of life over seizure prophylaxis. 1
• Levetiracetam monitoring should focus on seizure frequency and characteristics as the primary endpoint rather than serum levels alone, with emphasis on clinical response. 5

Alternative Agents (If Levetiracetam Fails or Is Poorly Tolerated)

• Consider switching to lamotrigine or lacosamide, both non-enzyme-inducing agents with favorable side-effect profiles in older adults. 1
• Avoid phenytoin, carbamazepine, and phenobarbital due to significant drug interactions, propensity for cognitive impairment, and heightened fall risk in elderly nursing home residents. 1
• Avoid valproate as an alternative in female patients where any potential for pregnancy exists. 1

Common Pitfalls to Avoid

• Do not automatically escalate the dose without first assessing whether the medication is still indicated, particularly in frail, bed-bound residents who may benefit more from deprescribing. 1
• Do not overlook medication non-adherence as the cause of subtherapeutic levels before making dosing changes. 1, 5
• Do not ignore renal function when adjusting doses, as elderly patients commonly have decreased creatinine clearance requiring dose reduction rather than escalation. 4, 2